



Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

February 10, 2026

Pivotal Phase 3 data from RAPIDe-3 of deucricitbant for the on-demand treatment of HAE attacks to be presented for the first time

ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- [Pharvaris](#) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for poster presentation, three of which will be presented during the Featured Poster session, at the [American Academy of Allergy, Asthma & Immunology \(AAAAI\) 2026 Annual Meeting](#), to be held from February 27-March 2, 2026, in Philadelphia, PA.

"Following the announcement of topline RAPIDe-3 data in December of last year, the AAAAI Annual Meeting provides Pharvaris with the first opportunity to share the positive study results with the broader medical community at a large scientific congress," said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. "We will also be presenting final data from the open-label portion of CHAPTER-1, the Phase 2 study of deucricitbant for prophylaxis of HAE attacks, and pharmacokinetic data of deucricitbant extended-release tablet, which is being used in the pivotal Phase 3 study of deucricitbant for long-term prophylaxis of HAE attacks, CHAPTER-3. Final efficacy and safety results from approximately three years of deucricitbant treatment from CHAPTER-1 and the data providing further evidence of an optimized extended-release formulation provide strong foundations in advance of the results of CHAPTER-3, topline data from which is anticipated in the third quarter of this year. Additionally, we will be presenting on-demand endpoint validation findings, as well as results from our novel kinin biomarker assay."

Details of the presentations are as follows:

- **Title:** A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema
Presenter: Evangelia Pardali, Ph.D.
Poster Number: 078
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
- **Title:** Content Validity of the Angioedema Symptom Rating Scale (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks
Presenter: Teresa Caballero, M.D., Ph.D.
Poster Number: 154
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
- **Title:** Long-Term Prophylactic Treatment with Oral Deucricitbant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
Presenter: Michael E. Manning, M.D.
Poster Number: 159
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST
- **Title:** Oral Deucricitbant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study
Presenter: Marc A. Riedl, M.D., M.S.
Featured Poster Number: 831
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
- **Title:** Long-Term Safety and Efficacy of Oral Deucricitbant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
Presenter: John Anderson, M.D.
Featured Poster Number: 832
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
- **Title:** Sustained Therapeutic Exposure with Once-Daily Oral Deucricitbant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
Presenter: Zhi-Yi Zhang, Ph.D.
Featured Poster Number: 834
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST

The abstracts are available to view in an online supplement to *The Journal of Allergy and Clinical Immunology* (JACI) at [jacionline.org](#).

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: [ir.pharvaris.com/news-events/events-presentations](#).

About Pharvaris

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris' aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing global

marketing authorization applications for deucricitbant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucricitbant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucricitbant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit <https://pharvaris.com/>.

Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications maggie.beller@pharvaris.com